Communication on biosimilar medicines

What are biological medicines? (2019)

Biosimilar approval is based on sound science (2019)

European experience: Biosimilars are safe and effective (2019)

Healthcare Professionals can count on biosimilars safety and effectiveness (2019)




The era of biological medicines
Since their first use in the 1980s, biological medicines (including biosimilar medicines) have grown to become an indispensable tool in modern medicine. Worldwide, millions of patients have already benefited from approved biological medicines, but what exactly are they, and how are they produced?



Biological medicines ― the major social and economic challenges

The global spend on pharmaceuticals continues to increase. The use of biological medicines offers new treatment choices to patients, but at a high financial cost. What are the challenges faced by payers and physicians in preserving access to biological medicines within a financially constrained healthcare system?



Biosimilar medicines — rising to the cost challenge

Addressing the rising cost of biological medicines has become a priority for governments and healthcare systems around the globe.
Biosimilar medicines are providing more cost-effective biological treatments, but what are biosimilar medicines, and how do they meet this challenge?



Biosimilar medicines — a commitment to scientific excellence

With biosimilar medicines, patients and healthcare providers benefit from high quality and efficacious therapeutic alternatives.
But how are biosimilar medicines developed, and how is their efficacy and safety ensured?



The benefits of biosimilar medicines
Biosimilar medicines have demonstrated similarity with reference biologicals in terms of structure, function, safety and efficacy, but what are their benefits?



Building on the experience and success of biosimilar medicines

Biosimilar medicines are increasingly becoming an integral part of modern healthcare systems, so what does the future hold?


If you are an IGBA Member and wish to use any part of this slide deck, please contact us at This email address is being protected from spambots. You need JavaScript enabled to view it. . We would be happy to share this with you.

Contact Info


Rue des Pierres-du-Niton 17
1207 Geneva

Telephone: +32 (0)2 5346607
This email address is being protected from spambots. You need JavaScript enabled to view it.  
This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site